drugset
drugset / Trial / NCT02002598

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

NCT02002598 ↗

Phase 1/2 Terminated 23 enrolled Suzanne Lentzsch, MD
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of carfilzomib (CFZ) in combination with bendamustine and dexamethasone for patients with newly diagnosed multiple myeloma (MM).

Timeline

Start
2013-11
Primary completion
2019-03-01
Completion
2023-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bendamustine Small molecule 60 mg/m2 Intravenous
Subject Bendamustine Small molecule 70 mg/m2 Intravenous
Subject Bendamustine Small molecule 90 mg/m2 Intravenous
Subject Carfilzomib Other / unclassified 27 mg/m2 Intravenous
Subject Carfilzomib Other / unclassified 36 mg/m2 Intravenous
Subject Carfilzomib Other / unclassified 45 mg/m2 Intravenous
Subject Carfilzomib Other / unclassified 56 mg/m2 Intravenous
Background Dexamethasone Small molecule 20 mg Oral

Indications

plasma cell myeloma